DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for tricuspid atresia — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleTricuspid atresia maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for tricuspid atresia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Tricuspid atresia is a complex congenital heart disease that presents with cyanosis in the neonatal period and is invariably fatal if left untreated. A 2020 literature review states that management requires multiple stages of palliation, with early recognition and timely surgical intervention being pivotal. The review notes that further work is needed to elucidate the aetiology of tricuspid atresia, clarify the role of pharmacotherapy, and optimise surgical management.
A 2008 case report describes a 3-month-old boy with tricuspid atresia who presented with dyspnoea, fever, cough and cyanosis. Following resuscitation, a central shunt from the ascending aorta to the main pulmonary artery was constructed. The patient did well despite a turbulent post-operative period. The report concludes that palliative treatment is possible and that definitive treatment, where possible, affords a fairly satisfactory prognosis.
A 2025 case report describes tricuspid atresia with transposition of the great arteries without pulmonary obstruction, a rare type that delays diagnosis due to late onset of cyanosis, which delays surgery. The report states that timely surgical interventions have contributed to converting the high mortality rate into a high survival rate. Clinicians are advised to consider the importance of early diagnosis to avoid irreversible changes that negatively affect surgical outcome.
What is still missing are prospective trials comparing different shunt types and timing, any randomised evidence for pharmacotherapy in tricuspid atresia, and patient stratification based on anatomical subtypes beyond single case reports. The 2020 review explicitly states that the role of pharmacotherapy remains unclear and that the aetiology of the condition is not yet elucidated.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Heart · 1953 · 58 citations · open access
CONGENITAL TRICUSPID ATRESIA
AbstractMany papers have been written on the diagnosis and prognosis of tricuspid atresia. Differences between various descriptions, especially in papers on X-ray features, may be explained partly by the rarity of the condition and partly by the effects produced by other complicating anomalies. Tri- cuspid atresia is responsible for only about 5 per cent of all cyanotic heart disease in infancy, and many patients die in the first few months of life. Consequently it is unlikely that any one centre will quickly collect a large series of cases and it may be of value to describe our findings in 15 patients on August 21, 2023 by guest.
Journal of Cardiac Surgery · 2020 · 32 citations · open access
Tricuspid atresia: Where are we now?
AbstractTricuspid atresia (TA) is a complex congenital heart disease that presents with cyanosis in the neonatal period. It is invariably fatal if left untreated and requires multiple stages of palliation. Early recognition and timely surgical intervention are therefore pivotal in the management of these infants. This literature review considers the pathophysiology, presentation, investigations, and classification of TA. Moreover, it discusses the evidence upon which the latest medical and surgical treatments are based, as well as numerous recent case reports. Further work is needed to elucidate the etiology of TA, clarify the role of pharmacotherapy, and optimize the surgical management that these patients receive.
Nigerian Journal of Medicine · 2008 · 0 citations · open access
Tricuspid Atresia with Normal Axis on ECG Palliated With A Central Shunt; A Case Report
AbstractBACKGROUND: Tricuspid Atresia is the 3rd commonest cyanotic congenital Heart disease. It is characterized by lack of communication between the right atrium and right ventricle. The treatment often requires a palliative systemic to pulmonary shunt before definite surgery. The use of a central shunt via a median sternotomy is suggested here as an alternative to other traditional shunts via a thoracotomy. METHOD: The management of a 3-month-old boy who presented with dyspnoea, fever, cough and cyanosis is presented here as obtained from Clinical records. RESULT: Following resuscitation, a central shunt (Ascending Aorta to main Pulmonary Artery) was constructed and the patient did well despite a turbulent post-operative period. CONCLUSION: The management of tricuspid atresia likes other cyanotic heart disease is daunting but palliative treatment is possible in our environment and definitive treatment where possible affords a fairly satisfactory prognosis.
Clinical Case Reports · 2025 · 0 citations · open access
Tricuspid Atresia and Transposition of the Great Arteries in a Neonate With Successful Surgical Correction: A Case Report
AbstractTricuspid atresia (TA) with transposition of the great arteries (TGA) without pulmonary obstruction is a rare type of TA that delays diagnosis due to late onset of cyanosis, which delays surgery, as timely surgical interventions have contributed to converting the high mortality rate into a high survival rate. Clinicians should take into consideration the importance of early diagnosis to avoid irreversible changes that negatively affect the surgical outcome.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
